OverviewSuggest Edit

Intra-Cellular Therapies is a biopharmaceutical company that is developing novel drugs for the treatment of diseases and disorders of the Central Nervous System (CNS). The Company develops compounds that have the potential to treat a wide range of diseases associated with the central nervous system. Intra-Cellular Therapies is developing its lead drug candidate, lumateperone, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders.

TypePublic
Founded2002
HQNew York, US
Websiteintracellulartherapies.com
Employee Ratings0

Latest Updates

Employees (est.) (Feb 2019)73(+49%)
Revenue (FY, 2017)$245.8 K(-25%)
Share Price (Mar 2019)$13.4

Key People/Management at Intra-Cellular Therapies

Sharon Mates

Sharon Mates

Founder, Chairman & Chief Executive Officer
Andrew Satlin

Andrew Satlin

Executive Vice President and Chief Medical Officer
Michael Halstead

Michael Halstead

Senior Vice President and General Counsel
Kimberly E. Vanover

Kimberly E. Vanover

Senior Vice President of Clinical Development
Robert E. Davis

Robert E. Davis

Senior Vice President, Chief Scientific Officer
Allen A. Fienberg

Allen A. Fienberg

Founder & Vice President of Business Development
Show more

Intra-Cellular Therapies Office Locations

Intra-Cellular Therapies has an office in New York
New York, US (HQ)
430 E 29th St #900
Show all (1)
Report incorrect company information

Intra-Cellular Therapies Financials and Metrics

Intra-Cellular Therapies Revenue

Intra-Cellular Therapies's revenue was reported to be $245.84 k in FY, 2017
USD

Net income (FY, 2018)

(155.1m)

EBIT (FY, 2018)

(162.3m)

Market capitalization (15-Mar-2019)

739.7m

Closing stock price (15-Mar-2019)

13.4

Cash (31-Dec-2018)

54.9m
Intra-Cellular Therapies's current market capitalization is $739.7 m.
Annual
USDFY, 2013FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

2.7m2.7m577.3k91.4k330.7k245.8k

Revenue growth, %

(79%)(84%)262%

General and administrative expense

6.0m10.3m18.2m24.8m23.7m30.1m

R&D expense

23.0m21.2m87.7m93.8m79.4m132.2m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

668.0k167.8k219.2k124.4k3.3k57.4k124.4k3.3k228.4k4.4k95.3k114.7k30.8k

General and administrative expense

1.3m1.9m2.1m2.6m3.8m4.0m3.9m5.1m6.5m6.3m6.3m6.3m5.3m6.4m13.1m

R&D expense

4.2m2.8m2.7m4.0m18.6m17.8m28.5m23.4m25.3m23.9m21.5m12.5m18.5m30.7m63.1m

Operating expense total

5.5m4.7m4.8m6.6m22.4m21.7m32.3m28.5m31.8m30.2m27.8m18.7m23.8m37.1m76.3m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

35.2m61.3m47.2m48.6m37.8m54.9m

Accounts Receivable

336.3k51.6k30.7k94.3k

Inventories

762.2k1.3m8.0m4.0m

Current Assets

38.2m131.0m483.3m388.2m469.2m355.4m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

44.1m143.6m91.1m68.9m100.8m71.4m332.8m37.2m52.0m200.4m23.6m29.6m52.3m74.4m69.8m

Accounts Receivable

251.3k167.8k219.2k124.4k3.3k9.1k51.6k98.2k1.3k68.2k61.9k6.3k

Current Assets

47.1m146.4m141.2m137.5m236.5m212.6m512.3m462.9m446.8m541.8m371.6m348.8m333.4m443.2m409.7m

PP&E

75.7k65.1k63.9k57.4k559.7k722.1k785.5k731.4k718.7k677.7k605.7k628.9k679.6k1.3m1.3m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(26.9m)(30.7m)(104.8m)(116.4m)(97.8m)(155.1m)

Depreciation and Amortization

23.2k25.5k139.6k196.9k213.9k368.7k

Inventories

Accounts Payable

3.4m(1.3m)(419.9k)2.1m2.4m7.8m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(4.9m)(4.5m)(9.1m)(6.4m)(22.3m)(43.8m)(32.2m)(27.8m)(58.7m)(88.9m)(26.9m)(44.7m)(67.6m)(35.5m)(72.9m)

Depreciation and Amortization

6.3k12.7k47.1k48.0k96.7k146.8k50.4k101.8k155.3k82.5k178.3k

Accounts Payable

(1.3m)(3.0m)503.9k4.6m2.9m705.0k326.4k2.3m3.8m3.4m(2.0m)653.0k3.9m(794.7k)

Cash From Operating Activities

(7.0m)(12.2m)(46.7m)(19.7m)(33.1m)(62.8m)(16.4m)(41.3m)(55.7m)(27.0m)(60.6m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Intra-Cellular Therapies Operating Metrics

FY, 2017

Patents and Patent Applications

80
Show all operating metrics

Intra-Cellular Therapies Revenue Breakdown

Embed Graph

Intra-Cellular Therapies revenue breakdown by business segment: 33.6% from License and collaboration revenue and 66.4% from Grant Revenue

Report incorrect company information

Intra-Cellular Therapies News and Updates

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update

NEW YORK, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and year ended December 31, 201…

Intra-Cellular Therapies stock down 22% after discontinuation of Phase 3 trial

Shares of Intra-Cellular Therapies Inc. plummeted 22% in pre-market trade Tuesday after the company announced it would discontinue its Phase 3 clinical trial of lumateperone for the treatment of agitation in patients with Alzheimer's disease. An interim analysis of the the trial concluded it would …

Intra-Cellular Therapies Announces Update on ITI-007-201 Clinical Trial for Treatment of Agitation in Patients with Probable Alzheimer's Disease

NEW YORK, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced an independent data monitoring committee (DMC) has completed a pre-specified …

Intra-Cellular Therapies Announces Favorable Results From Long-Term Open-Label Safety Switching Study With Lumateperone in Patients with Schizophrenia at the 57th Annual Meeting of the American College of Neuropsychopharmacology

Favorable safety results following administration of lumateperone for up to one year treatment duration are consistent with and extend the safety and tolerability profile previously reported in short-term trials

Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2018 Financial Results

NEW YORK, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today provided a corporate update and announced its financial results for the third quarter …

Intra-Cellular Therapies Announces Favorable Safety Profile for ITI-214 in a Phase 1/2 Clinical Trial in Patients with Parkinson’s Disease

Results show ITI-214 is associated with clinical signs consistent with improvements in motor symptoms and dyskinesias             
Show more
Report incorrect company information

Intra-Cellular Therapies Frequently Asked Questions

  • When was Intra-Cellular Therapies founded?

    Intra-Cellular Therapies was founded in 2002.

  • Who are Intra-Cellular Therapies key executives?

    Intra-Cellular Therapies's key executives are Sharon Mates, Andrew Satlin and Michael Halstead.

  • How many employees does Intra-Cellular Therapies have?

    Intra-Cellular Therapies has 73 employees.

  • Who are Intra-Cellular Therapies competitors?

    Competitors of Intra-Cellular Therapies include PhaseBio Pharmaceuticals, Microbion and Charles River Laboratories International.

  • Where is Intra-Cellular Therapies headquarters?

    Intra-Cellular Therapies headquarters is located at 430 E 29th St #900, New York.

  • Where are Intra-Cellular Therapies offices?

    Intra-Cellular Therapies has an office in New York.

  • How many offices does Intra-Cellular Therapies have?

    Intra-Cellular Therapies has 1 office.